

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

<https://marketpublishers.com/r/VDBF48B692F6EN.html>

Date: October 2019

Pages: 50

Price: US\$ 1,699.00 (Single User License)

ID: VDBF48B692F6EN

Abstracts

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline report-2020 is an annual R&D review of Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline candidates. The report presents the current status of all major Vancomycin Resistant Staphylococcus aureus (VRSA) Infections therapeutic compounds. Detailed insights into Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline development, current status, companies, drug profiles and Vancomycin Resistant Staphylococcus aureus (VRSA) Infections preclinical and clinical trials are included.

2020 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Market Insights

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Vancomycin Resistant Staphylococcus aureus (VRSA) Infections therapies, pipeline by phase and others are included.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline Drug profiles- Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Therapeutic Drug

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline Report 2020- Current Status, Phase,...

candidates

Both active and inactive Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline drug candidates are included in the report

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Clinical Trials and preclinical Studies

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline market developments

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline companies in active development

The report analyzes Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline of the below companies-

Century Therapeutics Inc, CrystalGenomics Inc, Debiopharm International SA, Destiny Pharma Ltd , iNtRON Biotechnology Inc, Therapeutic Systems Research Laboratories Inc, Wockhardt Ltd

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

7 Companies investing in Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Vancomycin Resistant Staphylococcus aureus (VRSA) Infections pipeline candidate are included

Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

Contents

1. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Disease Overview

1.2 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug Pipeline Snapshot, 2020

1.2.1 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Phase

1.2.2 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Company

1.2.3 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Mechanism of Action

1.2.4 Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs by Route of Administration

2. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS COMPANY WISE PIPELINE DETAILS

Century Therapeutics Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

CrystalGenomics Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Debiopharm International SA Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Destiny Pharma Ltd Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

iNtRON Biotechnology Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Therapeutic Systems Research Laboratories Inc Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Wockhardt Ltd Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Pipeline Drugs

Company Profile

Drug Candidate Details

3. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles

3.2 Phase 1 Drug Profiles

3.3 Phase 2 Drug Profiles

3.4 Phase 3 Drug Profiles

4. VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS (VRSA) INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology

5.2 Publisher Expertize

5.3 Contacts

I would like to order

Product name: Vancomycin Resistant Staphylococcus aureus (VRSA) Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/VDBF48B692F6EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VDBF48B692F6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970